 |
|
New drug aims to 'seek and destroy' many types of cancer
October 06, 2009A new drug designed to "seek and destroy" common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.
The Phase 1 clinical trial will help determine if EP-100 is safe and effective for use among patients with solid cancer tumors, with fewer side effects than chemotherapy or radiation treatment.
TCRS is a partnership of the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare. The partnership allows molecular and genomic discoveries made by TGen and others around the world to reach the patient bedside in the Virginia G. Piper Cancer Center at Scottsdale Healthcare as quickly as possible through clinical trials with agents directed at specific targets in patients' tumors.
Dr. Ramesh K. Ramanathan, M.D., principal investigator for the trial in Scottsdale, said the drug is a membrane-disrupting peptide (tMDP) designed to "seek and destroy" cancer cells by targeting those with excessive luteinizing hormone releasing hormone (LHRH) receptors.
Excessive LHRH receptors are found in a wide range of cancers, including breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers.
Dr. Mike Janicek, M.D., a Gynecologist Oncologist who practices at the Virginia G. Piper Cancer Center at Scottsdale Healthcare, said, "I am looking forward to participating in the study with EP100, especially for ovarian and uterine cancer patients. Often patients with advanced cancer will need new therapies and a targeted treatment like EP100 is the next frontier of research."
The study is designed to evaluate the safety of EP100 and will enroll as many as 36 adult patients with solid tumors whose tumor biopsies indicate that they have excessive LHRH receptors.
EP-100 will be administered intravenously for three out of four weeks. Once the maximum tolerated dose has been established, additional subjects with specific diagnoses of either breast, ovarian, endometrial, pancreatic or prostate cancer will be enrolled. EP-100 is produced by Esperance Pharmaceuticals of Baton Rouge, La., and was culled from a range of drugs tested at TGen Drug Development Services (TD2) in Scottsdale.
"It brings with it a killer, a toxin. It's a way of targeting a toxin to the cancer tumor cells,'' said Dr. Steve Gately, president and chief scientific advisor at TD2. "Our goal would be to find that set of patients who are highly responsive; who have the greatest benefit. We'd like to accelerate the government approval for that agent.''
The clinical trials could show that EP-100 is effective with certain types of cancer, Dr. Gately said. "Perhaps there is a genetic context under which certain patients may be more responsive. We want to find those patients.''
Dr. Hector Alila, president of Esperance, said EP-100 has the potential to offer an improved safety and effectiveness over existing therapies, such as radiation or chemotherapy.
"Preclinical studies of EP-100 demonstrated this candidate's efficacy across multiple indications in oncology, including aggressive cancers known to be resistant to the current standards of care and, importantly, studies of EP-100's mechanism-of-action support that it targets and selectively kills cancer cells without harming normal cells," Dr. Alila said.
The Translational Genomics Research Institute
Dr. Ramesh K. Ramanathan, M.D., principal investigator for the trial in Scottsdale, said the drug is a membrane-disrupting peptide (tMDP) designed to "seek and destroy" cancer cells by targeting those with excessive luteinizing hormone releasing hormone (LHRH) receptors.
Excessive LHRH receptors are found in a wide range of cancers, including breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers.
Dr. Mike Janicek, M.D., a Gynecologist Oncologist who practices at the Virginia G. Piper Cancer Center at Scottsdale Healthcare, said, "I am looking forward to participating in the study with EP100, especially for ovarian and uterine cancer patients. Often patients with advanced cancer will need new therapies and a targeted treatment like EP100 is the next frontier of research."
The study is designed to evaluate the safety of EP100 and will enroll as many as 36 adult patients with solid tumors whose tumor biopsies indicate that they have excessive LHRH receptors.
EP-100 will be administered intravenously for three out of four weeks. Once the maximum tolerated dose has been established, additional subjects with specific diagnoses of either breast, ovarian, endometrial, pancreatic or prostate cancer will be enrolled. EP-100 is produced by Esperance Pharmaceuticals of Baton Rouge, La., and was culled from a range of drugs tested at TGen Drug Development Services (TD2) in Scottsdale.
"It brings with it a killer, a toxin. It's a way of targeting a toxin to the cancer tumor cells,'' said Dr. Steve Gately, president and chief scientific advisor at TD2. "Our goal would be to find that set of patients who are highly responsive; who have the greatest benefit. We'd like to accelerate the government approval for that agent.''
The clinical trials could show that EP-100 is effective with certain types of cancer, Dr. Gately said. "Perhaps there is a genetic context under which certain patients may be more responsive. We want to find those patients.''
Dr. Hector Alila, president of Esperance, said EP-100 has the potential to offer an improved safety and effectiveness over existing therapies, such as radiation or chemotherapy.
"Preclinical studies of EP-100 demonstrated this candidate's efficacy across multiple indications in oncology, including aggressive cancers known to be resistant to the current standards of care and, importantly, studies of EP-100's mechanism-of-action support that it targets and selectively kills cancer cells without harming normal cells," Dr. Alila said.
The Translational Genomics Research Institute
Cancer Tumor Current Events and Cancer Tumor News RSSCommon pain relief medication may encourage cancer growth
Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells.
Small peptide found to stop lung cancer tumor growth in mice
In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world.
Waste disposal protein is mechanism behind cancer tumor suppression
"Taking out the trash" takes on a whole new meaning, as investigators at The Cancer Institute of New Jersey (CINJ) and Rutgers, The State University of New Jersey, have discovered that a waste disposal protein is the key to cancer tumor suppression in a process known as autophagy.
Research reveals molecular pathway behind invasive prostate cancers
University of Cincinnati (UC) cancer and cell biologists have identified a new molecular pathway key to the development of invasive prostate cancers.
The future of personalized cancer treatment: An entirely new direction for RNAi delivery
In technology that promises to one day allow drug delivery to be tailored to an individual patient and a particular cancer tumor, researchers at the University of California, San Diego School of Medicine, have developed an efficient system for delivering siRNA into primary cells.
Large study documents how p53 mutations link to high-grade breast cancer, poor outcomes
In what is believed to be the largest study of its kind in the US, researchers have found that almost 26 percent of women studied who have breast cancer have mutations in a gene important in controlling cell growth and death, and that patients with mutations in this gene -- known as p53 - had poorer outcomes including a significantly increased risk of death from the cancer.
UC Davis researchers identify a protein that may help breast cancer spread, beat cancer drugs
New research from UC Davis Cancer Center shows that a protein called Muc4 may be the essential ingredient that allows breast cancer to spread to other organs and resist therapeutic treatment.
Research shows biopsy of recurrent breast cancer can alter treatment
For women with recurrent breast cancer, the treatment the doctor chooses is usually based on the properties of their original breast cancer. A group from Toronto has recently completed the world's first study that compared original breast cancer tumors with a biopsy of suspected tumors that recurred elsewhere in the body.
NYU Langone Medical Center researchers find micro RNA plays a key role in melanoma metastasis
Scientists have long wondered how melanoma cells travel from primary tumors on the surface of the skin to the brain, liver and lungs, where they become more aggressive, resistant to therapy, and deadly.
The dietary supplement genistein can undermine breast cancer treatment
Women taking aromatase inhibitors to treat breast cancer or prevent its recurrence should think twice before also taking a soy-based dietary supplement, researchers report.
More Cancer Tumor Current Events and Cancer Tumor News Articles
 |
Childhood Cancer: A Parent's Guide to Solid Tumor Cancers, 2nd Edition by Honna Janes-Hodder (Author), Nancy Keene (Author) This second edition of the most complete parent guide available, features detailed and precise medical information about solid tumor childhood cancers, including neuroblastoma, Wilms tumor, liver tumors, soft tissue sarcomas, and bone sarcomas. In addition, it offers day-to-day practical advice on how to cope with procedures, hospitalization, family and friends, school, social and financial issues, communication, feelings, and, if therapy is not successful, the difficult issues of death and bereavement. Woven among the medical details and the practical advice are the voices of parents and children who have lived with cancer and its treatments. Parents who read this book will encounter medical facts simply explained, advice to ease their daily lives, and tools to be strong advocates for... |
 |
Lung Ablation: New Hope for Lung Cancer Combining the latest image-guided radiological and surgical techniques, radiofrequency ablation (RFA) uses a thin wire probe, inserted directly into tumors, to heat and kill cancer cells with electrical current. Employed successfully for years in liver, kidney and bone cancers, RFA has only recently been tested in lung cancer cases, with positive results. This fascinating episode of "Healthy Body, Healthy Mind" features Dr. Damian Dupuy, who has pioneered the use of ablation to treat lung cancer in the United States. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Maximum Intenational Maximize Graviola 750, 750mg Graviola, 100 Veggie Caps by Maximum International Having attracted worldwide interest as an inhibitor of malignant cell growth, this remarkable Amazonian herb has been studied in more than 20 laboratory tests for its anti-tumor and cell protective qualities. The best Graviola on the market. Maximum Int'l. is the company with the most potent products available. Lab tested to make sure the ingredients are of the most superior quality and highes quality raw materials available. This product is manufactured in an FDA inspected and GMP certified facility. Quality is guaranteed. |
 |
PetAlive C-Caps for Anti-Oxidant Support (60 Caps) by PetAlive PetAlive C-Caps contain a combination of especially selected and highly respected herbs known for their anti-tumor properties and their ability to optimize immune functioning. PetAlive C-Caps strengthen immune system to prevent and treat cancer and help in the prevention and treatment of cancer, with demonstrated anti-tumor properties; slow down the spread of cancer cells to surrounding tissue; improve compromised immune systems; accelerate healing and relieve fatigue and strengthen the lymphatic system to improve toxin build-up and promote waste elimination. |
 |
PetAlive C-Caps and DetoxPlus ComboPack by PetAlive The PetAlive ComboPack of C-Caps and DetoxPlus consists of multiple remedies that work well together to provide increased support for your pets condition. This ComboPack is effective for cancer support and systemic cleansing. The C-Caps strengthen immune system to prevent and treat cancer while the DetoxPlus cleanses the system and eliminates toxins from the body. |
 |
Tumor Has It Directed By: Adam Kassen Also With: Adam Kassen (Producer), Laura Kightlinger (Producer), Laura Kightlinger (Writer), David Punch (Producer), David Punch (Writer), Mark Kassen (Producer), Debbie DeMontreaux (Producer), Evan Shapiro (Producer), Rachel Smith (Producer) |
 |
Senator Ted Kennedy Memorial T-shirt, 5XL by Dreams2things No matter which political party you are a member of, endorse, or agree with most of the time.... There has not been a more dedicated public service leader than Ted Kennedy. Celebrate his life and legacy by wearing this beautiful memorial tshirt in his honor! |
 |
Cancer Be Gone Guided imagery CD taps into the immense power of the mind to enhance comfort, healing, an optimistic attitude and positive expectations. Metaphor of "cancer as weeds in a garden that are easily managed". |
 |
Cancer Vaccines and Tumor Immunity by Rimas Orentas (Author), James W. Hodge (Author), Bryon D. Johnson PhD (Author) Cancer Vaccines and Tumor Immunity offers a review of the basic scientific discoveries that have moved forward into clinical trials. Presented in the context of real-world human research and experimentation, these major scientific advances demonstrate how our understanding of immune activation, T-regulatory cells, and autoimmunity will impact cancer vaccine design. The authors also explain how vaccination in the context of bone marrow transplantation will open new avenues for clinical study in the future. |
 |
Tumors of the Brain and Spine (M.D. Anderson Cancer Care Series) by Franco DeMonte (Editor), Mark R. Gilbert (Editor), Anita Mahajan (Editor), Ian E. McCutcheon (Editor), R. Sawaya (Editor), W.K.A. Yung (Editor) Tumors of the Brain and Spine focuses primarily on the standard approaches to the treatment of benign, primary low-grade to high-grade, and metastatic tumors in the brain and spine used by surgeons and clinicians at The University of Texas M. D. Anderson Cancer Center. It is written mainly for the primary care oncologist, general neurologist, and general neurosurgeon. Chapters on treatment focus on neurosurgery, chemotherapy, and radiation therapy, both singly and in combination. Chapters on symptom management, the molecular genetics and neuropathology of intracranial tumors, the leptomeningeal dissemination of systemic cancer, the epidemiology of brain tumors, and innovative treatment strategies round out the volume. |
| © 2009 BrightSurf.com |